Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- Drug: Cadonilimab+Regorafenib+GC
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 30
- Registration Number
- NCT05820906
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis
Not Applicable
Recruiting
- Conditions
- Epiphora Due to Insufficient Drainage, Right SideEpiphora Due to Insufficient Drainage, Left Side
- Interventions
- Procedure: Esophagogastric End to Side AnastomosisProcedure: Esophagogastric Side to Side Anastomosis
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Target Recruit Count
- 402
- Registration Number
- NCT05812495
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
Phase 2
Not yet recruiting
- Conditions
- Resectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Target Recruit Count
- 50
- Registration Number
- NCT05807776
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting
Not Applicable
Completed
- Conditions
- Chemotherapy Induced Nausea and VomitingSquamous Cell Carcinoma of Head and Neck
- Interventions
- Other: nurse-led standardized intervention
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 92
- Registration Number
- NCT05792228
- Locations
- 🇨🇳
Tianjin medical universtiy cancer institute and hospital, Tianjin, Tianjin, China
Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs At Risk
Completed
- Conditions
- Breast CancerEsophageal CancerLung Cancer
- Interventions
- Device: contouring of thoracic organs at risk
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 500
- Registration Number
- NCT05787522
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China
The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.
Not Applicable
Recruiting
- Conditions
- Mammary Neoplasms, Human
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-23
- Target Recruit Count
- 43
- Registration Number
- NCT05781633
- Locations
- 🇨🇳
Yehui Shi, Tianjin, Tianjin, China
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
Phase 2
Not yet recruiting
- Conditions
- AnlotinibAumolertinibNSCLCTP53EGFR Activating Mutation
- Interventions
- Drug: Aumolertinib,Anlotinib
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 47
- Registration Number
- NCT05778149
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Completed
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Procedure: Selective extended dissection of pancreaticoduodenectomy
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Target Recruit Count
- 520
- Registration Number
- NCT05723978
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: Disitamab Vedotin Combined With Sintilimab
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Target Recruit Count
- 20
- Registration Number
- NCT05720533
© Copyright 2025. All Rights Reserved by MedPath